Novavax, Inc. (NVAX)
| Market Cap | 1.09B |
| Revenue (ttm) | 1.06B |
| Net Income (ttm) | 341.75M |
| Shares Out | 162.50M |
| EPS (ttm) | 2.07 |
| PE Ratio | 3.25 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,757,036 |
| Open | 6.70 |
| Previous Close | 6.72 |
| Day's Range | 6.60 - 6.74 |
| 52-Week Range | 5.01 - 11.55 |
| Beta | 2.37 |
| Analysts | Hold |
| Price Target | 9.75 (+45.09%) |
| Earnings Date | Nov 6, 2025 |
About NVAX
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adoles... [Read more]
Financial Performance
In 2024, Novavax's revenue was $682.16 million, a decrease of -30.65% compared to the previous year's $983.71 million. Losses were -$187.50 million, -65.60% less than in 2023.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for NVAX stock is "Hold." The 12-month stock price target is $9.75, which is an increase of 45.09% from the latest price.
News
FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks
A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.
Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men
Memo also reportedly mentions vaccines for flu and pneumonia.
Moderna and Novavax Stocks Drop as FDA Proposes Stricter Vaccine Approvals
The FDA's top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.
Novavax, Inc. (NVAX) Presents at Jefferies London Healthcare Conference 2025 Transcript
Novavax, Inc. ( NVAX) Jefferies London Healthcare Conference 2025 November 19, 2025 11:30 AM EST Company Participants Ruxandra Draghia-Akli - Executive VP and Head of Research & Development James Kel...
Shah Capital pushes for Novavax sale, warns of proxy fight
Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no progress is ...
Novavax to Participate in Jefferies London Healthcare Conference
GAITHERSBURG, Md. , Nov. 12, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the following upcoming investor conference: Jefferies London Healthcare Confe...
Novavax, Inc. (NVAX) Q3 2025 Earnings Call Transcript
Novavax, Inc. ( NVAX) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants John Jacobs - President, CEO & Director Ruxandra Draghia-Akli - Executive VP and Head of Research & Devel...
Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights
Total revenue of $70 million in the third quarter of 2025 Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date including $50 million earned on mar...
Novavax raises annual revenue forecast on strength of vaccine deals
Novavax raised its annual revenue forecast for the third time this year on Thursday, banking on milestone payments from vaccine supply and licensing deals such as with Japan's Takeda Pharmaceuticals.
Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment
Novavax has successfully achieved U.S. BLA approval and completed both EU and U.S. marketing authorization transfers for Nuvaxovid™ to Sanofi in line with its CLA and its corporate strategy, securing ...
Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025
GAITHERSBURG, Md. , Oct. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its third quarter 2025 financial results and operational highlights at 8:30 a.m.
Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy
Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million Novavax headquarters to remain in Gait...
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential
Shah Capital is reportedly pressing Novavax Inc. (NASDAQ:NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine.
Shah Capital pushes for Novavax's sale on persistent underperformance, marketing missteps
Shah Capital has urged Novavax's board to pursue a sale of the biotech, citing a third consecutive year of poor roll-out of its COVID-19 shot, the hedge fund said on Tuesday.
Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment
GAITHERSBURG, Md. , Oct. 7, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the marketing authorization for its COVID-19 vaccine, Nuvaxovid® to Sanofi, in the European ...
Novavax Announces Progress on Sanofi Agreement
GAITHERSBURG, Md. , Sept. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced progress on its collaboration and license agreement (CLA) with Sanofi regarding Novavax's Matrix-M® adju...
Mizuho's Jared Holz: There's not much value left in vaccine stocks
Jared Holz, Mizuho healthcare senior strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on pharmaceuticals, what new government vaccine panel recommendations mean for the stocks, and ...
Novavax, Inc. (NVAX) Presents At Cantor Global Healthcare Conference 2025 Transcript
Novavax, Inc. (NASDAQ:NVAX) Cantor Global Healthcare Conference 2025 September 4, 2025 10:20 AM EDT Company Participants John Jacobs - President, CEO & Director Ruxandra Draghia-Akli - Executive VP a...
Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment
GAITHERSBURG, Md. , Sept. 4, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced a milestone payment* from Takeda has been triggered by regulatory approval for Novavax's COVID-19 vaccine...
Novavax to Participate in the Cantor Global Healthcare Conference
GAITHERSBURG, Md. , Sept. 3, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the following upcoming investor conference: Cantor Global Healthcare Conferen...
Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.
Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season GAITHERSBURG, Md. , Aug. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX...
Novavax Announces Convertible Debt Refinancing
Refinancing extends maturity of most existing debt with improved terms $225 million of convertible notes due in 2031 issued, including a ~$175 million exchange for the retirement of existing convertib...
Novavax, Inc. (NVAX) Q2 2025 Earnings Call Transcript
Novavax, Inc. (NASDAQ:NVAX) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants James Patrick Kelly - Executive VP, CFO & Treasurer John Charles Jacobs - President, CEO & ...
Novavax beats quarterly revenue estimates on milestone payment
Novavax beat Wall Street expectations for second-quarter revenue on Wednesday, helped by a $175 million milestone payment related to U.S. approval of its COVID-19 vaccine in May.
Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights
Total revenue of $239 million in the second quarter of 2025 Received FDA BLA approval for Nuvaxovid™, the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the U.S.; approval trig...